About GNI Group
GNI Group is a publicly listed company based in Chiba (Japan) founded in 2001. Multinational company engaged in the research, development, manufacturing of pharmaceutical drugs. The company has 867 employees. GNI Group has completed 1 acquisition, including Ayumi Pharmaceutical. Its website gnipharma.com draws about 37 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals.
Company details
Gni pharma is engaged in the research, development, manufacturing and sales of pharmaceutical drugs and traditional Chinese medicines. The drug development pipeline includes tamibarotene for acute promyelocytic leukemia under preparation for import drug registration; F351 in phase 1 for liver fibrosis and for chronic kidney failure in preclinical stage; F573 for acute chronic liver failure in investigational new drug application stage; and etuary for pulmonary fibrosis (approved), for radiation pneumonitis in phase 2, for diabetic nephropathy in preclinical stage, and connective disease in preclinical stage
- Headquarters Chiba, Japan
- Employees 867
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website gnipharma.com
- Social X Facebook YouTube
- Legal Name Gni Group Ltd.
- Annual Revenue$171.31 M (USD)13.67as on Dec 31, 2025
- Net Profit-$27.06 M (USD)-486.44as on Dec 31, 2025
- EBITDA-$7.4 M (USD)-364.95as on Dec 31, 2025
- Employee Count867
- Investments & Acquisitions
Apps and channels of GNI Group
its YouTube channel お団子博士の医療実験室 [ ジーエヌアイグループ ] has 1.2K subscribers.
![お団子博士の医療実験室 [ ジーエヌアイグループ ] YouTube channel](https://yt3.googleusercontent.com/yotVBJPT5PcqzWDsiWgTlwh7ibuATua5N4hxEZzRgahns6wsyhgz9I8N3kXvTTF-TpOahdLhR9M=s900-c-k-c0x00ffffff-no-rj){kind=small}
People of GNI Group
6 people are tracked at GNI Group (1 in leadership, 5 in board & advisors); the tracked headcount is 867.
| Name | Role | Group |
|---|---|---|
Ying Luo | Director, Representative Executive Officer, President & CEO | Leadership |
Kan-Ichiro Suzuki | Director | Board & advisors |
Hideaki Sashiwa | Director | Board & advisors |
Kanako Kikuchi | External Director | Board & advisors |
Ryosuke Matsui | External Director | Board & advisors |
Sekitani Kazuki | External Director | Board & advisors |
Complete people profiles for GNI Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GNI Group
GNI Group is a publicly listed company on the TSE with ticker symbol 2160 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Aug 2007
- Listed onTSE: 2160
- Listed entityGNI Group Ltd.
- Exchange sectorHealth technology
- ISINJP3386370005
- Share price2,940.00 JPY (-4.39% on the day) · 2026-10-14
- Market capitalisation202,448,323,059.00 JPY
- EPS (diluted, trailing year)-95.48 JPY
- Volume (last session)2,102,900
Financials of GNI Group
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 26.84B JPY | -4.24B JPY | -1.16B JPY |
| 2024 | 23.61B JPY | 1.10B JPY | 436.7M JPY |
| 2023 | 26.01B JPY | 8.09B JPY | 5.19B JPY |
| 2022 | 17.42B JPY | 388.8M JPY | 1.76B JPY |
| 2021 | 12.69B JPY | 1.07B JPY | 1.50B JPY |
Detailed financial statements for GNI Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GNI Group
GNI Group has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ayumi Pharmaceutical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Specialty generic drugs for rheumatism and orthopedics are manufactured. | ayumi-pharma.com | Tokyo, Japan | 2015 | Jun 2026 | $279.43M |
Complete acquisition details for GNI Group
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of GNI Group
3 dated milestones of GNI Group across 25 years, from founding to its latest funding, stage changes and deals.
- Founded GNI Group is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Ayumi Pharmaceutical.
Web traffic of GNI Group
The website of GNI Group (gnipharma.com) receives about 37.5K visits a month.
- Monthly visits37.5K
▼ 13.7% vs previous month
Websites whose visitors overlap most with GNI Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
finance.yahoo.co.jp | finance.yahoo.co.jp | 100% | #530 | – | |
teiikabu.is-mine.net | teiikabu.is-mine.net | 91% | – | ||
kabutan.jp | kabutan.jp | 83% | #2,472 | – | |
ishare-emh.com | ishare-emh.com | 80% | #967,209 | – | |
| rakuten-sec.co.jp | 78% | 94.2M | #325 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for GNI Group
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gni Group
Complete news archive for GNI Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GNI Group
GNI Group was founded in 2001.
GNI Group is headquartered in Chiba, Japan. It is registered at Chiba, Chiba, Japan.
GNI Group has 867 employees.
Annual revenue of GNI Group is $171.31M as on Dec 31, 2025.
Gni pharma is engaged in the research, development, manufacturing and sales of pharmaceutical drugs and traditional Chinese medicines. The drug development pipeline includes tamibarotene for acute promyelocytic leukemia under preparation for import drug registration; F351 in phase 1 for liver fibrosis and for chronic kidney failure in preclinical stage; F573 for acute chronic liver failure in investigational new drug application stage; and etuary for pulmonary fibrosis (approved), for radiation pneumonitis in phase 2, for diabetic nephropathy in preclinical stage, and connective disease in preclinical stage.
Yes, GNI Group is publicly traded on TSE under the ticker symbol 2160.
GNI Group has made 1 acquisition, including Ayumi Pharmaceutical.